dc.contributor.author | Gregory, AE | |
dc.contributor.author | Titball, R | |
dc.contributor.author | Williamson, D | |
dc.date.accessioned | 2016-11-28T11:16:43Z | |
dc.date.issued | 2013 | |
dc.description.abstract | Vaccination has had a major impact on the control of infectious diseases. However, there are still many infectious diseases for which the development of an effective vaccine has been elusive. In many cases the failure to devise vaccines is a consequence of the inability of vaccine candidates to evoke appropriate immune responses. This is especially true where cellular immunity is required for protective immunity and this problem is compounded by the move toward devising sub-unit vaccines. Over the past decade nanoscale size (<1000 nm) materials such as virus-like particles, liposomes, ISCOMs, polymeric, and non-degradable nanospheres have received attention as potential delivery vehicles for vaccine antigens which can both stabilize vaccine antigens and act as adjuvants. Importantly, some of these nanoparticles (NPs) are able to enter antigen-presenting cells by different pathways, thereby modulating the immune response to the antigen. This may be critical for the induction of protective Th1-type immune responses to intracellular pathogens. Their properties also make them suitable for the delivery of antigens at mucosal surfaces and for intradermal administration. In this review we compare the utilities of different NP systems for the delivery of sub-unit vaccines and evaluate the potential of these delivery systems for the development of new vaccines against a range of pathogens. | en_GB |
dc.description.sponsorship | This work was partly supported by grant number U54 AI057156 from the Western Regional Centre for Excellence, USA. The study performed in the laboratory of RWT was supported by NIH/NIAID grant U54 AI057156 from the Western Regional Center for Excellence. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIAID or NIH. | en_GB |
dc.identifier.citation | Vol 3:13. doi: 10.3389/fcimb.2013.00013. | en_GB |
dc.identifier.doi | 10.3389/fcimb.2013.00013 | |
dc.identifier.uri | http://hdl.handle.net/10871/24615 | |
dc.language.iso | en | en_GB |
dc.publisher | Frontiers Media | en_GB |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/23532930 | en_GB |
dc.rights | This Document is Protected by copyright and was first published by Frontiers. All rights reserved. it is reproduced with permission. | en_GB |
dc.subject | adjuvant | en_GB |
dc.subject | antigen-presenting cell | en_GB |
dc.subject | immunity | en_GB |
dc.subject | nanoparticle | en_GB |
dc.subject | vaccine | en_GB |
dc.subject | Antigen-Presenting Cells | en_GB |
dc.subject | Drug Carriers | en_GB |
dc.subject | Immunity, Cellular | en_GB |
dc.subject | Nanoparticles | en_GB |
dc.subject | Th1 Cells | en_GB |
dc.subject | Vaccines, Subunit | en_GB |
dc.title | Vaccine delivery using nanoparticles | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2016-11-28T11:16:43Z | |
dc.identifier.issn | 2235-2988 | |
exeter.place-of-publication | Switzerland | en_GB |
dc.description | This is the final version of the article. Available from the publisher via the DOI in this record. | en_GB |
dc.identifier.journal | Frontiers in Cellular and Infection Microbiology | en_GB |
dc.identifier.pmcid | PMC3607064 | |
dc.identifier.pmid | 23532930 | |